skip to main content

EHDI: Early Hearing Detection & Intervention

mobile device menu button

Meeting: What you need to know before starting a Universal CMV screening program: Top 5 Considerations

Watch the pre-recorded sessions from Drs. Jessica Dunn and Mark Schleiss here


November 9, 2021 | 1:00 pm - 2:00 pm MT


While the COVID-19 pandemic may have postponed the CMV Public Health and Policy Conference, the work on CMV prevention, screening and education has not stopped. Join us as two experts in the field discuss considerations for starting a Universal CMV screening program. Drs. Jessica Dunn and Mark Schleiss will each address their top 5 considerations before starting a Universal CMV Screening program. After watching each of their 30-minute, pre-recorded sessions, there will be a live one-hour Q&A where they will be prepared to answer questions from you.

Learning Objectives

  1. Name at least two considerations in starting a universal CMV screening program.
  2. List a minimum of three stakeholders who should be involved in a universal CMV screening program.
  3. Discuss the role of parent involvement in implementing a universal CMV screening program.

Presenter Information

Mark Schleiss MD

Dr. Schleiss is a Professor of Pediatrics and holds the American Legion and Auxiliary Endowed Research Chair at the University of Minnesota Medical School. His laboratory is supported by the NIH and March of Dimes Birth Defects Foundation. He conducts research in small animal models testing vaccine strategies against congenital CMV infection. His laboratory is also engaged in the study of the epidemiology, pathogenesis and management of congenital and neonatal CMV infections.

Jessica Dunn MD, MPH

Dr. Jessica Dunn, MD, MPH is a Pediatric Infectious Disease specialist at Alberta Children’s Hospital and Clinical Assistant Professor at the Cumming School of Medicine, University of Calgary. She earned her medical degree and Master of Public Health at Boston University, then pursued her Pediatric and Infectious Diseases post-graduate training at the University of Ottawa. She played a key role in the development of Newborn Screening Ontario’s CMV screening program as a risk factor for hearing loss, the first of its kind in the world, and continues to serve as the medical lead for this provincial program.